Fuan Pharmaceutical's wholly-owned subsidiary, Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Ceftazidime Avibactam Sodium for Injection issued by the National Medical Products Administration. The drug specification is 2.5 grams, registered as a Category 4 chemical drug, and is deemed to have passed the consistency evaluation. It is indicated for the treatment of complicated intra-abdominal infections, hospital-acquired pneumonia, and ventilator-associated pneumonia, among others. Currently, a total of 22 companies have passed or are deemed to have passed the consistency evaluation for this drug. The company stated that this approval will further enrich the subsidiary's product pipeline, but the impact on performance remains uncertain.
Fuan Pharmaceutical Group CoSubsidiary obtains drug registration certificate for Ceftazidime Avibactam Sodium, enriching pipeline.